Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 1:14 p.m.

    📋 OPTINOSE, INC. (OPTN) - Clinical Trial Update

    Filing Date: 2022-07-13

    Accepted: 2022-07-13 07:00:31

    Event Type: Clinical Trial Update

    Event Details:

    OptiNose Inc (OPTN) Announces Clinical Trial Update OptiNose Inc (OPTN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: visits, patients
    • Diseases/Conditions: 70% of visits, chronic rhinosinusitis per year
    • Clinical Stage: Phase 3
    • Collaboration: ENT

    🔬 Clinical Development Pipeline (OPTINOSE, INC.):

    Product Type Development Stage Therapeutic Area Source
    OPN-375 DRUG Phase PHASE3 Bilateral Nasal Polyposis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: OptiNose Inc
    • CIK: 0001494650
    • Ticker Symbol: OPTN
    • Period End Date: 2022-07-13
    • Document Type: 8-K

Search

News categories